Citius Oncology Files 8-K: Equity Sale, Officer Changes, Financials
Ticker: CTOR · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1851484
Sentiment: neutral
Topics: equity-sale, management-change, financials
TL;DR
CITIUS filed an 8-K: unregistered equity sale, director/officer changes, and financials released.
AI Summary
On September 19, 2025, Citius Oncology, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The filing also announced the departure of a director, the election of a new director, and the appointment of certain officers, alongside updates on compensatory arrangements for these officers. Additionally, the report included financial statements and exhibits.
Why It Matters
This filing provides crucial updates on Citius Oncology's corporate structure and financial dealings, potentially impacting investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity and changes in leadership, which can introduce uncertainty and potential risks.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- September 19, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal Executive Office Address
- TenX Keane Acquisition (company) — Former Company Name
- 20210315 (date) — Date of Name Change
FAQ
What type of equity securities were sold in the unregistered sale?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type or amount of securities sold in this 8-K.
Who is the departing director and who is the newly elected director?
The filing indicates the departure of a director and the election of a new director, but their names are not provided in the excerpt.
What are the specific changes in officer appointments?
The filing mentions the appointment of certain officers, but the specific roles and individuals are not detailed in this excerpt.
What are the details of the compensatory arrangements for the officers?
The filing notes updates on compensatory arrangements for certain officers, but the specifics are not included in the provided text.
What financial statements and exhibits are included with this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content of these documents is not detailed in the excerpt.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-19 17:00:51
Key Financial Figures
- $2.1875 — common stock with an exercise price of $2.1875 per shares, that are exercisable on Mar
Filing Documents
- ea0257909-8k_citius.htm (8-K) — 24KB
- ea025790901ex10-1_citius.htm (EX-10.1) — 7KB
- 0001213900-25-089615.txt ( ) — 196KB
- ctor-20250919.xsd (EX-101.SCH) — 3KB
- ctor-20250919_lab.xml (EX-101.LAB) — 33KB
- ctor-20250919_pre.xml (EX-101.PRE) — 22KB
- ea0257909-8k_citius_htm.xml (XML) — 4KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. On September 19, 2025, Citius Oncology, Inc. (the "Company) issued to a financial advisor warrants to purchase up to 360,000 shares of our common stock with an exercise price of $2.1875 per shares, that are exercisable on March 10, 2026, and that expire on March 10, 2031. The warrants were issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
02 Departure of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 19, 2025, the board of directors of the Company approved an amendment to the Company's 2024 Omnibus Stock Incentive Plan (the "2024 Plan") to increase the authorized number of shares of the Company's common stock reserved for issuance thereunder from an aggregate of 15,000,000 shares to an aggregate of 30,000,000 shares. Other than the increase in the shares reserved for issuance under the 2024 Plan, there were no other changes to the 2024 Plan made by the amendment. A copy of the full text of the amendment to the 2024 Plan is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 10.1 Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 19, 2025 CITIUS ONCOLOGY, INC. By: /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2